In a separate case report, a patient with Philadelphia chromosome-positive B-ALL, who relapsed after CD19 targeted CAR therapy, was treated with the combination of blinatumomab (bi-specific T cell engagers against CD19 and CD3) and ponatinib (multi-tyrosine kinase inhibitor) [115]. Here, CD19 is linked to acute lymphoblastic leukemia.